Literature DB >> 26515137

Reprint of Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina.

M A Gadan1, S J González2, M Batalla3, M S Olivera3, L Policastro2, M L Sztejnberg3.   

Abstract

In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  HER2-enriched breast cancer; Immunoliposomes; Post treatment recurrences

Year:  2015        PMID: 26515137     DOI: 10.1016/j.apradiso.2015.10.009

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  3 in total

Review 1.  Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer.

Authors:  Danushka Seneviratne; Pooja Advani; Daniel M Trifiletti; Saranya Chumsri; Chris J Beltran; Aaron F Bush; Laura A Vallow
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 2.  Boron neutron capture therapy: Current status and future perspectives.

Authors:  Mayya Alexandrovna Dymova; Sergey Yurjevich Taskaev; Vladimir Alexandrovich Richter; Elena Vladimirovna Kuligina
Journal:  Cancer Commun (Lond)       Date:  2020-08-17

3.  In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.

Authors:  Diego Alberti; Alessia Michelotti; Alberto Lanfranco; Nicoletta Protti; Saverio Altieri; Annamaria Deagostino; Simonetta Geninatti Crich
Journal:  Sci Rep       Date:  2020-11-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.